Feedback
Settings

Settings

Goto Application

3,759 results
Offices all Languages Stemming true Single Family Member false Include NPL false
RSS feed can only be generated if you have a WIPO account

Save query

A private query is only visible to you when you are logged-in and can not be used in RSS feeds

Query Tree

Refine Options

Offices
All
Specify the language of your search keywords
Stemming reduces inflected words to their stem or root form.
For example the words fishing, fished,fish, and fisher are reduced to the root word,fish,
so a search for fisher returns all the different variations
Returns only one member of a family of patents
Include Non-Patent literature in results

Full Query

CHEM:(FPUGCISOLXNPPC-IOSLPCCCSA-N)

Side-by-side view shortcuts

General
Go to Search input
CTRL + SHIFT +
Go to Results (selected record)
CTRL + SHIFT +
Go to Detail (selected tab)
CTRL + SHIFT +
Go to Next page
CTRL +
Go to Previous page
CTRL +
Results (First, do 'Go to Results')
Go to Next record / image
/
Go to Previous record / image
/
Scroll Up
Page Up
Scroll Down
Page Down
Scroll to Top
CTRL + Home
Scroll to Bottom
CTRL + End
Detail (First, do 'Go to Detail')
Go to Next tab
Go to Previous tab

Analysis

1 / 376
1.WO/2026/018181IMMUNOGENIC COMPOSITIONS AND USES THEREOF
WO - 22.01.2026
Int.Class A61K 39/12
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
39Medicinal preparations containing antigens or antibodies
12Viral antigens
 Appl.No PCT/IB2025/057203 Applicant PFIZER INC. Inventor HUANG, Bridget Yih Jiin
The present disclosure relates to RSV F, hMPV F, PIV3 F, PIV3 HN, PIV1 F and PIV1 HN protein mutants, nucleic acids or vectors encoding them, compositions comprising a RSV F, hMPV F, PIV3 F, PIV3 HN, PIV1 F and/or PIV1 HN nucleic acid or combinations thereof, and uses thereof.
2.WO/2026/019998VACCINES FOR KAPOSI'S SARCOMA-ASSOCIATED HERPESVIRUS
WO - 22.01.2026
Int.Class A61K 39/245
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
39Medicinal preparations containing antigens or antibodies
12Viral antigens
245Herpetoviridae, e.g. herpes simplex virus
 Appl.No PCT/US2025/038046 Applicant THE CLEVELAND CLINIC FOUNDATION Inventor JUNG, Jae
Provided herein are compositions, systems, kits, and methods for immunizing a subject against Kaposi's sarcoma-associated herpesvirus (KSHV) with a composition: i) comprising a plurality of nanoparticles self-assembled from a plurality of fusion proteins that comprise: a) at least a portion of a Ferritin protein, and b) an immunogenic protein comprising at least a portion of: KSHV K8.1 protein, or ii) polynucleotides encoding said fusion proteins (e.g., human codon optimized mRNA sequences present in lipid nanoparticles). In other embodiments, provided herein are compositions, systems, and kits, and methods for immunizing a subject against KSHV employing a human codon optimized nucleic acid sequence (e.g., mRNA) encoding a KSHV K8.1 protein.
3.WO/2026/013624DOUBLE STRANDED RNAI AGENTS, COMPOSITIONS AND METHODS OF USE
WO - 15.01.2026
Int.Class C12N 15/113
CCHEMISTRY; METALLURGY
12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
15Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
09Recombinant DNA-technology
11DNA or RNA fragments; Modified forms thereof
113Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides
 Appl.No PCT/IB2025/057021 Applicant NOVARTIS AG Inventor HUNZIKER, Juerg
Disclosed are, inter alia, double stranded RNAi (dsRNAi) agents inhibiting expression of 3-hydroxy-3-methylglutaryl-CoA reductase (HMGCR), for example, human HMGCR, compositions including the same, and methods of treatment using the same.
4.WO/2026/014855FUSION PROTEIN COMPRISING APOLIPOPROTEIN AND FC REGION-BINDING PEPTIDE AND USES THEREOF
WO - 15.01.2026
Int.Class C07K 14/775
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
14Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
435from animals; from humans
775Apolipopeptides
 Appl.No PCT/KR2025/009774 Applicant RNAGENE INC. Inventor LEE, Woo Ghil
The present invention relates to a fusion protein and a use thereof, wherein the fusion protein comprises: an apolipoprotein or a fragment thereof; and an Fc-binding peptide (Fc BP) or a fragment thereof. According to one aspect, a lipid carrier comprising the fusion protein was found to exhibit remarkably improved targeting efficiency, and thus can be used to deliver an active substance to a desired target.
5.WO/2026/015876IMPROVED METHODS FOR IN VITRO TRANSCRIPTION
WO - 15.01.2026
Int.Class C12P 19/34
CCHEMISTRY; METALLURGY
12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
PFERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
19Preparation of compounds containing saccharide radicals
26Preparation of nitrogen-containing carbohydrates
28N-glycosides
30Nucleotides
34Polynucleotides, e.g. nucleic acids, oligoribonucleotides
 Appl.No PCT/US2025/037414 Applicant ARCTURUS THERAPEUTICS, INC. Inventor HILL, Brett Dallas
Disclosed herein are methods of producing transcribed RNA product with increased yield and reduced RNA degradation.
6.WO/2026/010842USE OF LIPID NANOPARTICLE MRNA FOR TERT SPECIFIC CANCER IMMUNOTHERAPY
WO - 08.01.2026
Int.Class A61K 39/00
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
39Medicinal preparations containing antigens or antibodies
 Appl.No PCT/US2025/035853 Applicant THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA Inventor VONDERHEIDE, Robert H.
The present invention relates to compositions for inducing an immune response against a tumor antigen in a subject, the composition comprising at least one mRNA encoding at least one tumor antigen selected from the group consisting of hTERT, mTERT, and KRASG12D, encapsulated in a lipid nanoparticle.
7.WO/2026/008025IDO1 CANCER VACCINES AND USES THEREOF
WO - 08.01.2026
Int.Class A61K 38/08
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
38Medicinal preparations containing peptides
04Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
08Peptides having 5 to 11 amino acids
 Appl.No PCT/CN2025/106892 Applicant EVEREST MEDICINES (CHINA) CO., LTD. Inventor KAUDER, Steven
Provided herein are nucleic acids, pharmaceutical compositions and vaccines that express a cancer antigen comprising IDO1. Also provided herein are methods for treating a cancer.
8.WO/2026/008026PD-L1 CANCER VACCINES AND USES THEREOF
WO - 08.01.2026
Int.Class A61K 38/08
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
38Medicinal preparations containing peptides
04Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
08Peptides having 5 to 11 amino acids
 Appl.No PCT/CN2025/106893 Applicant EVEREST MEDICINES (CHINA) CO., LTD. Inventor KAUDER, Steven
Provided herein are nucleic acids, pharmaceutical compositions and vaccines that express a cancer antigen comprising PD-L1. Also provided herein are methods for treating a cancer.
9.WO/2026/009933COMPOSITION FOR IN VITRO TRANSCRIPTION REACTION AND IN VITRO TRANSCRIPTION REACTION METHOD
WO - 08.01.2026
Int.Class C12N 15/10
CCHEMISTRY; METALLURGY
12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
15Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
09Recombinant DNA-technology
10Processes for the isolation, preparation or purification of DNA or RNA
 Appl.No PCT/JP2025/023894 Applicant FUJIFILM TOYAMA CHEMICAL CO., LTD. Inventor TANAKA, Keita
This composition comprises: at least one buffer selected from the group consisting of 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid and 2-morpholinoethanesulfonic acid; and a capping reagent containing a capping compound capable of bonding to a terminal of a transcription reaction product, wherein the buffer concentration is 5-35 mM, and the pH is 5.0-7.5.
10.WO/2026/011165TRANSFERRIN RECEPTOR (TFR) APTAMERS AND USE THEREOF
WO - 08.01.2026
Int.Class C12N 15/115
CCHEMISTRY; METALLURGY
12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
15Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
09Recombinant DNA-technology
11DNA or RNA fragments; Modified forms thereof
115Aptamers, i.e. nucleic acids binding a target molecule specifically and with high affinity without hybridising therewith
 Appl.No PCT/US2025/036528 Applicant CREYON BIO, INC. Inventor WARNER, Matthew, John
The invention relates to compounds comprising advantageous novel aptamers and aptamer conjugates, as well as compositions comprising the same, and their use in therapy or diagnosis. In particular, disclosed herein are aptamers and aptamer conjugates that bind to the human transferrin receptor (1) (hTfRl) without competing with human transfenin (hTf) for binding to hTfRl.
# -